Editorial: sofosbuvir plus daclatasvir for the treatment of hepatitis C—can one size fit all?

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2036|47|6|853-854

ISSN： 0269-2813

Source： ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol.47, Iss.6, 2018-03, pp. : 853-854

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III study

By  

HEPATOLOGY, Vol. 61, Iss. 4, 2015-04 ,pp. : 1127-1135

John Wiley & Sons Inc

Access to resources Recommend Favorite

Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real‐world results from 18 378 patients in Egypt

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 47, Iss. 3, 2018-02 ,pp. : 421-431

John Wiley & Sons Inc

Access to resources Recommend Favorite

Sofosbuvir plus daclatasvir with or without ribavirin in 551 patients with hepatitis C‐related cirrhosis, genotype 4

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 47, Iss. 5, 2018-03 ,pp. : 674-679

John Wiley & Sons Inc

Access to resources Recommend Favorite

Sofosbuvir plus daclatasvir with or without ribavirin is safe and effective for post‐transplant hepatitis C recurrence and severe fibrosis and cirrhosis: A prospective study

By  

CLINICAL TRANSPLANTATION (ELECTRONIC), Vol. 32, Iss. 2, 2018-02 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite

Sofosbuvir plus simeprevir treatment of recurrent genotype 1 hepatitis C after liver transplant

By  

CLINICAL TRANSPLANTATION (ELECTRONIC), Vol. 29, Iss. 12, 2015-12 ,pp. : 1105-1111

John Wiley & Sons Inc

Access to resources Recommend Favorite